Yamagishi S - Search Results

1

Iridoids are natural glycation inhibitors.

West BJ, Deng S, Uwaya A, Isami F, Abe Y, Yamagishi S, Jensen CJ. West BJ, et al. Among authors: yamagishi s. Glycoconj J. 2016 Aug;33(4):671-81. doi: 10.1007/s10719-016-9695-x. Epub 2016 Jun 15. Glycoconj J. 2016. PMID: 27306206 Review.

2

Incadronate disodium inhibits advanced glycation end products-induced angiogenesis in vitro.

Okamoto T, Yamagishi S, Inagaki Y, Amano S, Takeuchi M, Kikuchi S, Ohno S, Yoshimura A. Okamoto T, et al. Among authors: yamagishi s. Biochem Biophys Res Commun. 2002 Sep 20;297(2):419-24. doi: 10.1016/s0006-291x(02)02218-0. Biochem Biophys Res Commun. 2002. PMID: 12237136

3

Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin.

Okamoto T, Yamagishi S, Inagaki Y, Amano S, Koga K, Abe R, Takeuchi M, Ohno S, Yoshimura A, Makita Z. Okamoto T, et al. Among authors: yamagishi s. FASEB J. 2002 Dec;16(14):1928-30. doi: 10.1096/fj.02-0030fje. Epub 2002 Oct 4. FASEB J. 2002. PMID: 12368225

4

Serum levels of glucose-derived advanced glycation end products are associated with the severity of diabetic retinopathy in type 2 diabetic patients without renal dysfunction.

Koga K, Yamagishi S, Okamoto T, Inagaki Y, Amano S, Takeuchi M, Makita Z. Koga K, et al. Among authors: yamagishi s. Int J Clin Pharmacol Res. 2002;22(1):13-7. Int J Clin Pharmacol Res. 2002. PMID: 12395914

5

Advanced glycation end product (age) inhibitors and their therapeutic implications in diseases.

Takeuchi M, Yamagishi S, Iwaki M, Nakamura K, Imaizumi T. Takeuchi M, et al. Among authors: yamagishi s. Int J Clin Pharmacol Res. 2004;24(2-3):95-101. Int J Clin Pharmacol Res. 2004. PMID: 15689055 Review.

6

[Molecular mechanism of diabetic retinopathy: role of advanced glycation end products(AGEs) and their receptor (RAGE) in the pathogenesis of diabetic retinopathy].

Yamagishi S, Imaizumi T. Yamagishi S, et al. Nippon Ganka Gakkai Zasshi. 2005 Jun;109(6):338-45. Nippon Ganka Gakkai Zasshi. 2005. PMID: 16047941 Review. Japanese.

7

Advanced glycation end-products attenuate human mesenchymal stem cells and prevent cognate differentiation into adipose tissue, cartilage, and bone.

Kume S, Kato S, Yamagishi S, Inagaki Y, Ueda S, Arima N, Okawa T, Kojiro M, Nagata K. Kume S, et al. Among authors: yamagishi s. J Bone Miner Res. 2005 Sep;20(9):1647-58. doi: 10.1359/JBMR.050514. Epub 2005 May 23. J Bone Miner Res. 2005. PMID: 16059636 Free article.

8

Possible participation of advanced glycation end products in the pathogenesis of osteoporosis in diabetic patients.

Yamagishi S, Nakamura K, Inoue H. Yamagishi S, et al. Med Hypotheses. 2005;65(6):1013-5. doi: 10.1016/j.mehy.2005.07.017. Med Hypotheses. 2005. PMID: 16146671

9

Inhibition by advanced glycation end products (AGEs) of pigment epithelium-derived factor (PEDF) gene expression in microvascular endothelial cells.

Yamagishi S, Matsui T, Inoue H. Yamagishi S, et al. Drugs Exp Clin Res. 2005;31(5-6):227-32. Drugs Exp Clin Res. 2005. PMID: 16425980

10

Role of advanced glycation end products (AGEs) in thrombogenic abnormalities in diabetes.

Takenaka K, Yamagishi S, Matsui T, Nakamura K, Imaizumi T. Takenaka K, et al. Among authors: yamagishi s. Curr Neurovasc Res. 2006 Feb;3(1):73-7. doi: 10.2174/156720206775541804. Curr Neurovasc Res. 2006. PMID: 16472128 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

931 results

Search Page

Filters